Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 77Leukemia 74Leukemia, Lymphocytic, Chronic, B-Cell 68Myelodysplastic Syndromes 56Lymphoma 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma, Non-Hodgkin 45Multiple Myeloma 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 38Hodgkin Disease 36Melanoma 25Hematologic Neoplasms 25Recurrence 19Neoplasms 17Myeloproliferative Disorders 17Neoplasm Metastasis 15Lymphoma, Follicular 15Primary Myelofibrosis 14Neoplasms, Plasma Cell 14Lymphoma, Large B-Cell, Diffuse 14Lymphoma, Mantle-Cell 13Skin Neoplasms 11Graft vs Host Disease 11Burkitt Lymphoma 11Anemia, Refractory, with Excess of Blasts 11Lymphoma, B-Cell, Marginal Zone 10Lymphoma, B-Cell 10Leukemia, Myelomonocytic, Chronic 9Hematologic Diseases 8Breast Neoplasms 8

Interventions

siltuximab 1otelixizumab 1fludarabine 1axicabtagene ciloleucel 1Leukapheresis 1Interleukin 1 Receptor Antagonist Protein 1Gelsolin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cytokine Release Syndrome × fludarabine × Clear all
NCT02761915 2021-08-17

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Cancer Research UK

Phase 1 Completed
17 enrolled 17 charts
CNS

Cytokine Release Syndrome, Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡